Apex Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Apex Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$5.62M	Buy	200,997 +34,658	+21%	+$756K	0.12%	147
2015 Q4	$5.93M	Buy	166,339 +12,513	+8%	+$441K	0.13%	143
2015 Q3	$5.09M	Buy	153,826 +14,021	+10%	+$583K	0.12%	145
2015 Q2	$5.86M	Buy	139,805 +11,375	+9%	+$440K	0.13%	138
2015 Q1	$4.19M	Buy	128,430 +34,903	+37%	+$1.2M	0.1%	161
2014 Q4	$2.97M	Buy	93,527 +22,445	+32%	+$636K	0.08%	166
2014 Q3	$1.76M	Buy	71,082 +7,107	+11%	+$166K	0.05%	174
2014 Q2	$1.45M	Buy	63,975 +8,791	+16%	+$184K	0.04%	180
2014 Q1	$1.34M	Buy	+55,184	New	+$1.4M	0.05%	183

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Apex Capital Management's ACAD Position: Q1 2016 in Review

Apex Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 21% in Q1 2016, buying an estimated $756K and bringing the position to 200,997 shares worth $5.62M. The position accounts for 0.12% of the portfolio, ranked #147.

Apex Capital Management first reported a position in ACAD in Q1 2014 and has held it in 9 quarters since. The position peaked at $5.93M in Q4 2015. 213 funds tracked by Wall St. Rank hold ACAD as of Q1 2016.

Apex Capital Management held 200,997 shares of Acadia Pharmaceuticals worth $5.62M as of Q1 2016.
Apex Capital Management bought 34,658 Acadia Pharmaceuticals shares in Q1 2016, an estimated $756K.
Acadia Pharmaceuticals made up 0.12% of Apex Capital Management's portfolio in Q1 2016, its #147 holding.
Apex Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2014 and has held it in 9 quarters since.
Apex Capital Management's Acadia Pharmaceuticals position peaked at $5.93M in Q4 2015.
213 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.